Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
1998 2
2002 1
2003 2
2005 7
2006 9
2007 7
2008 8
2009 7
2010 1
2011 3
2012 5
2013 3
2014 2
2015 3
2017 3
2018 4
2019 1
2020 1
2021 4
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant chemotherapy for ovarian cancer.
Vergote I, van Gorp T, Amant F, Neven P, Berteloot P. Vergote I, et al. Among authors: berteloot p. Oncology (Williston Park). 2005 Nov;19(12):1615-22; discussion 1623-30. Oncology (Williston Park). 2005. PMID: 16396153 Review.
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
Loverix L, Vergote I, Busschaert P, Vanderstichele A, Venken T, Boeckx B, Harter P, Brems H, Van Nieuwenhuysen E, Pignata S, Baert T, Gonzalez-Martin A, Han S, Marth C, Neven P, Colombo N, Berteloot P, Mäenpää J, Olbrecht S, Laga T, Sablon E, Ray-Coquard I, Pujade-Lauraine E, Lambrechts D, Van Gorp T. Loverix L, et al. Among authors: berteloot p. Eur J Cancer. 2023 Jul;188:131-139. doi: 10.1016/j.ejca.2023.04.020. Epub 2023 Apr 27. Eur J Cancer. 2023. PMID: 37245441
Timing of debulking surgery in advanced ovarian cancer.
Vergote I, van Gorp T, Amant F, Leunen K, Neven P, Berteloot P. Vergote I, et al. Among authors: berteloot p. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:11-9. doi: 10.1111/j.1525-1438.2007.01098.x. Int J Gynecol Cancer. 2008. PMID: 18336393 Review.
Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Floris G, Richard F, Hamy AS, Jongen L, Wildiers H, Ardui J, Punie K, Smeets A, Berteloot P, Vergote I, De Croze D, Meseure D, Salomon A, Laé M, Reyal F, Biganzoli E, Neven P, Desmedt C. Floris G, et al. Among authors: berteloot p. J Natl Cancer Inst. 2021 Feb 1;113(2):146-153. doi: 10.1093/jnci/djaa090. J Natl Cancer Inst. 2021. PMID: 33152071 Free PMC article.
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
Vanderstichele A, Loverix L, Busschaert P, Van Nieuwenhuysen E, Han SN, Concin N, Callewaert T, Olbrecht S, Salihi R, Berteloot P, Neven P, Lambrechts D, Van Gorp T, Vergote I. Vanderstichele A, et al. Among authors: berteloot p. Gynecol Oncol. 2022 Apr;165(1):14-22. doi: 10.1016/j.ygyno.2022.01.034. Epub 2022 Feb 14. Gynecol Oncol. 2022. PMID: 35177277 Clinical Trial.
Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort.
Thijssen S, Wildiers H, Punie K, Beuselinck B, Clement P, Remmerie C, Berteloot P, Han S, Van Nieuwenhuysen E, Van Gorp T, Vergote I, Smeets A, Nevelsteen I, Floris G, Weltens C, Menten J, Janssen H, Laenen A, Neven P. Thijssen S, et al. Among authors: berteloot p. J Cancer Res Clin Oncol. 2021 Apr;147(4):1041-1048. doi: 10.1007/s00432-020-03487-1. Epub 2021 Jan 20. J Cancer Res Clin Oncol. 2021. PMID: 33471187 Clinical Trial.
66 results